Search

Edwards Lifesciences Corp

Затворен

СекторЗдравеопазване

85.64 2.51

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

82.71

Максимум

85.47

Ключови измерители

By Trading Economics

Приходи

290M

381M

Продажби

92M

1.7B

P/E

Средно за сектора

49.429

64.641

EPS

0.78

Марж на печалбата

23.092

Служители

16,000

EBITDA

20M

520M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+22.94% upside

Дивиденти

By Acuity

Следващи печалби

29.10.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-1.1B

48B

Предишно отваряне

83.13

Предишно затваряне

85.64

Настроения в новините

By Acuity

55%

45%

253 / 340 Класиране в Healthcare

Edwards Lifesciences Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

28.07.2026 г., 18:46 ч. UTC

News

UBS analyst Danielle Antalffy initiated coverage on Edwards Lifesciences with a Buy rating and $110 price target, boosting shares modestly higher today.

27.07.2026 г., 19:41 ч. UTC

Social Media
News

Edwards Lifesciences shares rise as TAVR revenue hits $35 million, driven by a 10.5% increase in U.S. sales, surpassing expectations.

24.07.2026 г., 18:41 ч. UTC

News

Edwards Lifesciences Corp is trading lower today despite positive analyst ratings. The stock pulled back from an earlier session high and has declined since Thursday's close.

23.07.2026 г., 23:41 ч. UTC

News
Event

Edwards Lifesciences reported Q2 sales of $1.74 billion, exceeding expectations. Shares are gaining in after-market hours following the results and raised guidance.

22.07.2026 г., 18:46 ч. UTC

Edwards Lifesciences shares are trading higher during Wednesday's session, showing slight gains despite recent declines in the broader market.

21.07.2026 г., 21:02 ч. UTC

Edwards Lifesciences Corp shares are lower in after-market hours, continuing a trend of three consecutive sessions below the 20-day moving average.

20.07.2026 г., 19:56 ч. UTC

News

Edwards Lifesciences shares are lower as regulatory challenges arise from a $12 million FTC penalty and new restrictions on valve replacement agreements.

Сравнение с други в отрасъла

Ценова промяна

Edwards Lifesciences Corp Прогноза

Ценова цел

By TipRanks

22.94% нагоре

12-месечна прогноза

Среден 102.88 USD  22.94%

Висок 110 USD

Нисък 85 USD

Според 19 анализатори от Wall Street, предложили 12-месечна ценова цел за Edwards Lifesciences Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

19 ratings

16

Купи

3

Задържане

0

Продай

Настроение

By Acuity

253 / 340 Класиране в Здравеопазване

Настроения в новините

Мечи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Edwards Lifesciences Corp

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
help-icon Live chat